Invitae sees FY17 revenue approximately $59M, consensus $68.41M
Preliminary financial results for 2017 include: 127% year-over-year growth in volume for the base business, excluding acquisitions, to more than 134,000 samples accessioned compared to approximately 59,000 in 2016. The results exceeded the high end of the company's previously increased projected range of 120,000-130,000 samples. 136% growth in revenue in the base business to approximately $59M, excluding acquisitions. Results were within the company's $55-$65 million revenue guidance. Including results from acquisitions, the company expects to report full-year 2017 accessioned volume totalling approximately 150,000 samples generating approximately $67M in total revenue. Invitae's acquisition of Good Start Genetics closed in early August 2017, and its acquisition of CombiMatrix closed in mid-November 2017.